Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Axonics Modulation Technologies Inc is a medical devices business based in the US. Axonics Modulation Technologies shares (AXNX) are listed on the NASDAQ and all prices are listed in US Dollars. Axonics Modulation Technologies employs 517 staff and has a trailing 12-month revenue of around $217.4 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $70.44 |
|---|---|
| 52-week range | $38.41 - $79.92 |
| 50-day moving average | $70.26 |
| 200-day moving average | $58.65 |
| Wall St. target price | $87.13 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.81 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $70.44 from 2022-09-30
| 1 week (2022-09-23) | 7.97% |
|---|---|
| 1 month (2022-09-02) | -0.30% |
| 3 months (2022-07-01) | 21.53% |
| 6 months (2022-03-29) | N/A |
| 1 year (2021-10-01) | 5.40% |
|---|---|
| 2 years (2020-10-02) | 44.64% |
| 3 years (2019-10-02) | 177.98% |
| 5 years (2017-09-28) | N/A |
| Revenue TTM | $217.4 million |
|---|---|
| Gross profit TTM | $115.7 million |
| Return on assets TTM | -7.75% |
| Return on equity TTM | -16.25% |
| Profit margin | -35.19% |
| Book value | $9.29 |
| Market capitalisation | $3.2 billion |
TTM: trailing 12 months
We're not expecting Axonics Modulation Technologies to pay a dividend over the next 12 months.
Over the last 12 months, Axonics Modulation Technologies's shares have ranged in value from as little as $38.41 up to $79.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axonics Modulation Technologies's is 0.4153. This would suggest that Axonics Modulation Technologies's shares are less volatile than average (for this exchange).
Axonics, Inc. , a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.